Q-omics provides the consensus-scored BEGAIN profile across patient tissues and cancer cell-line models. BEGAIN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BEGAIN is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, BEGAIN RNA expression shows 13,784 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where BEGAIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEGAIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEGAIN survival associations across molecular data types. BEGAIN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEGAIN RNA expression–survival associations across cancer types. High BEGAIN expression shows unfavorable associations in ACC, LUAD, CESC, SKCM and OV, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BEGAIN RNA expression.
This table summarizes BEGAIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BEGAIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEGAIN shows lower tumor expression in THCA, UCEC, BRCA, BLCA and KICH and higher tumor expression in LIHC. The THCA box plot shows higher BEGAIN RNA expression in normal versus tumor tissue (log2 FC = −0.295, t-test p < 0.001).
This table shows molecular features associated with BEGAIN in patient tissues and cancer cell lines. In patient samples, BEGAIN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BEGAIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
